A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C
- 1 May 2001
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Gastroenterology & Hepatology
- Vol. 13 (5), 483-488
- https://doi.org/10.1097/00042737-200105000-00004
Abstract
Combination of interferon (IFN) alpha and ribavirin is considered the standard treatment for patients with chronic hepatitis C. While combination therapy is more effective than IFN alone, the optimal management of combination treatment remains uncertain.To assess a pragmatic and cost-effective strategy for the therapy of treatment-naive patients with chronic hepatitis C.Markov model on original data of two randomized trials.A validated computer simulation model was applied to non-cirrhotic hepatitis C virus (HCV)-infected patients. Patient characteristics and efficacy of treatment were extracted from two randomized trials reporting on 1,445 non-cirrhotic patients. Different strategies were compared separately for genotype 1 and genotype non-1 (mostly genotype 2/3) infections: (1) no treatment; (2) IFN for 48 weeks (if at 12 weeks HCV RNA undetectable); (3) IFN and ribavirin for 24 weeks; (4) IFN and ribavirin for 48 weeks; (5) IFN and ribavirin for 48 weeks (if at 24 weeks HCV RNA undetectable). All strategies were tested for different combinations of known response factors.In genotype non-1 infection, 24 weeks of combination therapy dominates all other strategies. In genotype 1 infection, 48 weeks of combination therapy for week-24 responders only prolongs life expectancy at a favourable cost-effectiveness ratio (CE) of 7,135 euros per quality-adjusted life year (QALY). Taking response factors other than genotype into account does not add to the effectiveness or cost effectiveness.Treating non-cirrhotic patients with chronic hepatitis C according to genotype only is most cost effective independent of the number of other known response factors.Keywords
This publication has 17 references indexed in Scilit:
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusThe Lancet, 1998
- Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis CThe Lancet, 1998
- Cost-Effectiveness of 6 and 12 Months of Interferon-α Therapy for Chronic Hepatitis CAnnals of Internal Medicine, 1997
- Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patientsGastroenterology, 1997
- Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and durationHepatology, 1996
- Long-Term Mortality after Transfusion-Associated Non-A, Non-B HepatitisNew England Journal of Medicine, 1992
- Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitisJournal of Hepatology, 1992
- Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitisHepatology, 1991
- Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virusHepatology, 1990